Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes

Statistics in Biopharmaceutical Research

Volumn 7, Issue 1, 2015, Pages 36-54

  Hamasaki, Toshimitsu ^a,b   Asakura, Koko ^a,b   Evans, Scott R ^c   Sugimoto, Tomoyuki ^d   Sozu, Takashi ^e  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d HIROSAKI UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Adaptive Type I error allocation; Average sample number; Equally or unequally spaced increments of information; Hierarchical testing procedure; Maximum sample size

Indexed keywords

ANALYTICAL ERROR; ARTICLE; BEHAVIOR; CLINICAL TRIAL; DECISION MAKING; HUMAN; METHODOLOGY; MONTE CARLO METHOD; NULL HYPOTHESIS; POWER ANALYSIS; PROBABILITY; SAMPLE SIZE; SEQUENTIAL ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS;

EID: 84925248994     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2014.1003090     Document Type: Article

References (28)

1. Asakura, K., Hamasaki, T., Evans, S.R., Sugimoto, T., and Sozu, T. (2015), “Sample Size Determination in Group-Sequential Clinical Trials with Two Co-Primary Endpoints,” in Applied Statistics in Biomedicine and Clinical Trial Design, eds. Z. Chen, Berlin: Springer (in press).
2. Asakura, K., Hamasaki, T., Sugimoto, T., Hayashi, K., Evans, S.R., and Sozu, T. (2014), “Sample Size Determination in Group-Sequential Clinical Trials with Two Co-Primary Endpoints,” Statistics in Medicine, 33, 2897–2913.
3. Cheng, Y., Ray, S., Chang, M., and Menon, S. (2014), “Statistical Monitoring of Clinical Trials with Multiple Co-Primary Endpoints Using Multivariate B-Value,” Statistics in Biopharmaceutical Research, 6, 241–250.
4. Committee for Medicinal Products for Human Use (CHMP) (2008), “Guideline on Medicinal Products for the Treatment Alzheimer's Disease and Other Dementias” (CPMP/EWP/553/95 Rev.1), London: EMEA.
5. Cui, L., Hung, H.M. J., and Wang, S.J. (1999), “Modification of Sample Size in Group Sequential Clinical Trials,” Biometrics, 55, 853–857.
6. Chuang-Stein, C., Stryszak, P., Dmitrienko, A., and Offen, W. (2007), “Challenge of Multiple Co-Primary Endpoints: A New Approach,” Statistics in Medicine, 26, 1181–1192.
7. Eaton, M.L., and Muirhead, RJ.J. (2007), “On Multiple Endpoints Testing Problem,” Journal of Statistical Planning & Inference, 137, 3416–3429.
8. Glimm, E., Maurer, W., and Bretz, F. (2010), “Hierarchical Testing of Multiple Endpoints in Group-Sequential Trials,” Statistics in Medicine, 29, 219–228.
9. Hamasaki, T., Sugimoto, T., Evans, S.R., and Sozu, T. (2013), “Sample Size Determination for Clinical Trials with Co-Primary Outcomes: Exponential Event Times,” Pharmaceutical Statistics, 12, 28–34.
10. Hung, HM. J.M. J., and Wang, SJ.J. (2009), “Some Controversial Multiple Testing Problems in Regulatory Applications,” Journal of Biopharmaceutical Statistics, 19, 1–11.
11. Hung, H.M. J., Wang, S.J., and O’Neill, R.T. (2007), “Statistical Considerations for Testing Multiple Endpoints in Group Sequential or Adaptive Clinical Trials,” Journal of Biopharmaceutical Statistics, 17, 1201–1210.
12. Genz, A. (1992), “Numerical Computation of Multivariate Normal Probabilities,” Journal of Computational and Graphical Statistics, 1, 141–149.
13. Julious, S., and Mclntyre, NE.E. (2012), “Sample Sizes for Trials Involving Multiple Correlated Must-Win Comparisons,” Pharmaceutical Statistics, 11, 177–185.
14. Kordzakhia, G., Siddiqui, O., and Huque, MF.F. (2010), “Method of Balanced Adjustment in Testing Co-Primary Endpoints,” Statistics in Medicine, 29, 2055–2066.
15. Lan, KK. G.K. G., and DeMets, DL.L. (1983), “Discrete Sequential Boundaries for Clinical Trials,” Biometrika, 70, 659–663.
16. O’Brien, PC.C., and Fleming, TR.R. (1979), “A Multiple Testing Procedure for Clinical Trials,” Biometrics, 35, 549–556.
17. Offen, W., Chuang-Stein, F, Dmitrienko, A., Littman, G., Maca, J., Meyerson, L., Muirhead, R., Stryszak, P., Boddy, A., Chen, K., Copley-Merriman, K., Dere, W., Givens, S., Hall, D., Henry, D., Jackson, JD.D., Krishen, A., Liu, T., Ryder, S., Sankoh, AJ.J., Wang, J., and Yeh, CH.H. (2007), “Multiple Co-Primary Endpoints: Medical and Statistical Solutions,” Drug Information Journal, 41, 31–46.
18. Pocock, SJ.J. (1977), “Group Sequential Methods in the Design and Analysis of Clinical Trials,” Biometrika, 64, 191–199.
19. Senn, S., and Bretz, F. (2007), “Power and Sample Size when Multiple Endpoints Are Considered,” Pharmaceutical Statistics, 6, 161–170.
20. Sozu, T., Sugimoto, T., and Hamasaki, T. (2010), “Sample Size Determination in Clinical Trials with Multiple Co-Primary Binary Endpoints,” Statistics in Medicine, 29, 2169–2179.
21. ——— (2011), “Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints,” Journal of Biopharmaceutical Statistics, 21, 1–19.
22. Sozu, TA.A., and Hamasaki, T. (2012), “Sample Size Determination in Clinical Trials with Multiple Co-Primary Endpoints Including Mixed Continuous and Binary Variables,” Biometrical Journal, 54, 716–729.
23. Sozu, T., Sugimoto, T., Hamasaki, T., and Evans S.R. (2015), Sample Size Determination in Clinical Trials with Multiple Primary Endpoints, Berlin: Springer (in press).
24. Sugimoto, T., Sozu, T., and Hamasaki, T. (2012), “A Convenient Formula for Sample Size Calculations in Clinical Trials with Multiple Co-Primary Continuous Endpoints,” Pharmaceutical Statistics, 11, 118–128.
25. Sugimoto, T., Sozu, T., Hamasaki, T., and Evans, S.R. (2013), “A Logrank Test-Based Method for Sizing Clinical Trials with Two Co-Primary Time-to-Event Endpoints,” Biostatistics, 14, 409–421.
26. Xiong, C., Yu, K., Gao, F., Yan, Y., and Zhang, Z. (2005), “Power and Sample Size for Clinical Trials When Efficacy Is Required in Multiple Endpoints: Application to An Alzheimer's Treatment Trial,” Clinical Trials, 2, 387–393.
27. Tamhane, A.C., Mehta, C.R., and Liu, L. (2010). “Testing A Primary and Secondary Endpoint in A Group Sequential Design,” Biometrics, 66, 1174–1184.
28. Tsong, Y., Zhang, J., and Wang, S.J. (2004), “Group Sequential Design and Analysis of Clinical Equivalence Assessment for Generic Nonsystematic Drug Products,” Journal of Biopharmaceutical Statistics, 14, 359–373.